Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
South Asian Bar Association of North America Annual Conference
Sponsorship
Axinn Named Antitrust Law Firm of the Year at the Chambers USA Awards 2026
News
Antitrust
Chambers USA Awards 2026
Sponsorship
Antitrust
ABA 2026 Antitrust International Cartel Workshop
Speaking Engagement
Antitrust
Axinn Earns Recognition in the Legal 500 2026 U.S. Guide for Antitrust and Litigation
News
Antitrust
Axinn Attorneys Featured in 2026 Lawdragon 500 X – The Next Generation Guide
News
Antitrust

